WSA
SRPT icon

Wall Street Associates’s Sarepta Therapeutics SRPT Stock Holding History

Wall Street Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-68,054
Closed -$2.59M – 315
2013
Q2 		$2.59M Buy
+68,054
New +$2.43M 0.26% 120

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Wall Street Associates's SRPT Position: Q3 2013 in Review

Wall Street Associates sold out of Sarepta Therapeutics (SRPT) in Q3 2013, closing a stake of 68,054 shares — an estimated $2.59M sold.

Wall Street Associates first reported a position in SRPT in Q2 2013 and held it in 1 quarter. The position peaked at $2.59M in Q2 2013. 134 funds tracked by Wall St. Rank hold SRPT as of Q3 2013.

  • Wall Street Associates reported no remaining Sarepta Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Wall Street Associates sold 68,054 Sarepta Therapeutics shares in Q3 2013, an estimated $2.59M.
  • Wall Street Associates first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 1 quarter.
  • Wall Street Associates's Sarepta Therapeutics position peaked at $2.59M in Q2 2013.
  • 134 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2013.

Based on Wall Street Associates's 13F filing for Q3 2013, filed 12 Nov 2013.